In This Article:
As the U.S. market navigates a mixed landscape with the Dow Jones Industrial Average reaching record highs and investors closely monitoring inflation data, growth stocks continue to capture attention for their potential returns. In this environment, companies with high insider ownership can be particularly appealing, as they often signal confidence from those who know the business best.
Top 10 Growth Companies With High Insider Ownership In The United States
| Name | Insider Ownership | Earnings Growth |
| Atour Lifestyle Holdings (NasdaqGS:ATAT) | 26% | 25.7% |
| Super Micro Computer (NasdaqGS:SMCI) | 14.4% | 24.3% |
| Duolingo (NasdaqGS:DUOL) | 14.6% | 41.6% |
| On Holding (NYSE:ONON) | 19.1% | 29.6% |
| Coastal Financial (NasdaqGS:CCB) | 18% | 46.1% |
| EHang Holdings (NasdaqGM:EH) | 32.8% | 81.5% |
| Alkami Technology (NasdaqGS:ALKT) | 11% | 98.6% |
| BBB Foods (NYSE:TBBB) | 22.9% | 44.2% |
| Credo Technology Group Holding (NasdaqGS:CRDO) | 13.7% | 95% |
| Credit Acceptance (NasdaqGS:CACC) | 14.1% | 50% |
Let's explore several standout options from the results in the screener.
ARS Pharmaceuticals
Simply Wall St Growth Rating: ★★★★★☆
Overview: ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for severe allergic reactions, with a market cap of approximately $1.33 billion.
Operations: The company generates its revenue from the Pharmaceuticals segment, amounting to $2.57 million.
Insider Ownership: 19.6%
Earnings Growth Forecast: 69.8% p.a.
ARS Pharmaceuticals, with significant insider ownership, is poised for substantial growth. The company forecasts a robust annual revenue increase of 55.5%, significantly outpacing the US market average. Recent developments include a licensing agreement with ALK-Abelló for neffy®, securing an upfront payment of US$145 million and potential milestones up to US$320 million. Despite current losses, ARS's innovative products and strategic partnerships position it well for future profitability within three years.
Afya
Simply Wall St Growth Rating: ★★★★★☆
Overview: Afya Limited is a medical education group operating in Brazil with a market cap of $1.52 billion.
Operations: The company's revenue segments include Undergrad at R$2.78 billion and Continuing Education at R$164.55 million.
Insider Ownership: 23.7%
Earnings Growth Forecast: 21.2% p.a.
Afya, with strong insider ownership, is set for significant earnings growth of 21.2% annually, surpassing the US market average. Despite slower revenue growth at 9.8%, it remains above the market rate and trades at a substantial discount to its estimated fair value. Recent financial results show improved third-quarter performance with net income rising to BRL 119.98 million from BRL 93.35 million year-over-year, affirming its positive trajectory amidst reaffirmed annual guidance.